NCCN Task Force report: Bone health and cancer care Journal Article
| Authors: | Theriault, R. L.; Biermann, J. S.; Brown, E.; Brufsky, A.; Demers, L.; Grewal, R. K.; Guise, T.; Jackson, R.; McEnery, K.; Podoloff, D.; Ravdin, P.; Shapiro, C. L.; Smith, M.; Van Poznak, C. H. |
| Article Title: | NCCN Task Force report: Bone health and cancer care |
| Abstract: | Higher incidences of osteoporosis and osteopenia are found in cancer patients, particularly in women receiving aromatase inhibitors or with chemotherapy-induced ovarian failure, or in men with prostate cancer and androgen deprivation therapy. Therefore, management of long-term bone health is emerging as an important aspect of comprehensive cancer care. Patients with cancer typically have a number of additional risk factors for osteoporosis that should prompt screening, regardless of patient age or sex. Maintaining bone health requires a broad knowledge base, including understanding underlying bone metabolism and how it is affected by both cancer itself and the drugs used to treat cancer, the effect of chemotherapy-induced menopause on bone health, bone markers and imaging techniques used to assess bone health, therapeutic strategies to maintain bone health, and treatment of bone metastases, including surgery for pathologic fractures. Multiple members of the healthcare team may need to be involved in education and care of the patient. This report summarizes discussion of these and other issues regarding bone health and cancer care from the NCCN Bone Health and Cancer Care Task Force meeting in early 2006. © Journal of the National Comprehensive Cancer Network. |
| Keywords: | cancer chemotherapy; unclassified drug; androgen; clinical trial; cancer risk; drug efficacy; drug safety; bone metastasis; conference paper; cancer adjuvant therapy; cancer radiotherapy; chemotherapy; drug inhibition; unindexed drug; computer assisted tomography; breast cancer; incidence; aromatase inhibitor; estrogen; bisphosphonates; calcitonin; calcium; hypercalcemia; diagnostic imaging; bone density; ovary insufficiency; monoclonal antibody; drug hypersensitivity; prostate cancer; goserelin; alkaline phosphatase; drug mechanism; vitamin d; collagen; tamoxifen; health care personnel; vitamin supplementation; world health organization; letrozole; osteoporosis; taxane derivative; menopause; postmenopause; aromatase inhibitors; parathyroid hormone; alendronic acid; drug induced disease; zoledronic acid; osteoprotegerin; osteoclast differentiation factor; follitropin; rib fracture; inhibin; phosphonic acid derivative; bone turnover; dual energy x ray absorptiometry; hip fracture; vertebra fracture; bone metabolism; bone health; dual x-ray absorptiometry; bone mineral density; osteopenia; bone metastases; pamidronic acid; denosumab; ibandronic acid; risedronic acid; selective estrogen receptor modulator; parathyroid hormone[1-34]; nccn clinical practice guidelines in oncology; pathologic fracture; osteocalcin; biphosphonate deivative; strontium |
| Journal Title: | Journal of the National Comprehensive Cancer Network |
| Volume: | 4 |
| Issue: | Suppl.2 |
| ISSN: | 1540-1405 |
| Publisher: | Harborside Press |
| Date Published: | 2006-05-01 |
| Start Page: | S1 |
| End Page: | S20 |
| Language: | English |
| PROVIDER: | scopus |
| PUBMED: | 16737674 |
| DOI/URL: | |
| Notes: | --- - "Cited By (since 1996): 21" - "Export Date: 4 June 2012" - "Source: Scopus" |
